Close Menu

NEW YORK (GenomeWeb News) – Theradiag said today that it has received the CE Mark for two new biotherapy monitoring kits: tocilizumab and rituximab. Tocilizumab is an immunosuppressive drug used to treat rheumatoid arthritis and juvenile idiopathic arthritis, while rituximab is prescribed for treatment of leukemia and lymphoma. The Theradiag kits are sold under the Lisa Tracker brand name.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.